Copyright Reports & Markets. All rights reserved.

Global GLP-1 Receptor Agonist Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global GLP-1 Receptor Agonist Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Short-acting Preparations
    • 1.3.3 Long-acting Preparations
    • 1.3.4 Ultra-long-acting Preparations
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global GLP-1 Receptor Agonist Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Type 2 Diabetes
    • 1.4.3 Obesity
  • 1.5 Global GLP-1 Receptor Agonist Drugs Market Size & Forecast
    • 1.5.1 Global GLP-1 Receptor Agonist Drugs Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global GLP-1 Receptor Agonist Drugs Sales Quantity (2021-2032)
    • 1.5.3 Global GLP-1 Receptor Agonist Drugs Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Novo Nordisk
    • 2.1.1 Novo Nordisk Details
    • 2.1.2 Novo Nordisk Major Business
    • 2.1.3 Novo Nordisk GLP-1 Receptor Agonist Drugs Product and Services
    • 2.1.4 Novo Nordisk GLP-1 Receptor Agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Novo Nordisk Recent Developments/Updates
  • 2.2 Eli Lilly
    • 2.2.1 Eli Lilly Details
    • 2.2.2 Eli Lilly Major Business
    • 2.2.3 Eli Lilly GLP-1 Receptor Agonist Drugs Product and Services
    • 2.2.4 Eli Lilly GLP-1 Receptor Agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Eli Lilly Recent Developments/Updates
  • 2.3 AstraZeneca
    • 2.3.1 AstraZeneca Details
    • 2.3.2 AstraZeneca Major Business
    • 2.3.3 AstraZeneca GLP-1 Receptor Agonist Drugs Product and Services
    • 2.3.4 AstraZeneca GLP-1 Receptor Agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 AstraZeneca Recent Developments/Updates
  • 2.4 Sanofi
    • 2.4.1 Sanofi Details
    • 2.4.2 Sanofi Major Business
    • 2.4.3 Sanofi GLP-1 Receptor Agonist Drugs Product and Services
    • 2.4.4 Sanofi GLP-1 Receptor Agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Sanofi Recent Developments/Updates
  • 2.5 GSK
    • 2.5.1 GSK Details
    • 2.5.2 GSK Major Business
    • 2.5.3 GSK GLP-1 Receptor Agonist Drugs Product and Services
    • 2.5.4 GSK GLP-1 Receptor Agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 GSK Recent Developments/Updates
  • 2.6 Hanson
    • 2.6.1 Hanson Details
    • 2.6.2 Hanson Major Business
    • 2.6.3 Hanson GLP-1 Receptor Agonist Drugs Product and Services
    • 2.6.4 Hanson GLP-1 Receptor Agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Hanson Recent Developments/Updates
  • 2.7 Shanghai Renhui Biopharmaceutical
    • 2.7.1 Shanghai Renhui Biopharmaceutical Details
    • 2.7.2 Shanghai Renhui Biopharmaceutical Major Business
    • 2.7.3 Shanghai Renhui Biopharmaceutical GLP-1 Receptor Agonist Drugs Product and Services
    • 2.7.4 Shanghai Renhui Biopharmaceutical GLP-1 Receptor Agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Shanghai Renhui Biopharmaceutical Recent Developments/Updates
  • 2.8 Huadong Medicine
    • 2.8.1 Huadong Medicine Details
    • 2.8.2 Huadong Medicine Major Business
    • 2.8.3 Huadong Medicine GLP-1 Receptor Agonist Drugs Product and Services
    • 2.8.4 Huadong Medicine GLP-1 Receptor Agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Huadong Medicine Recent Developments/Updates
  • 2.9 Sino Biopharm
    • 2.9.1 Sino Biopharm Details
    • 2.9.2 Sino Biopharm Major Business
    • 2.9.3 Sino Biopharm GLP-1 Receptor Agonist Drugs Product and Services
    • 2.9.4 Sino Biopharm GLP-1 Receptor Agonist Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Sino Biopharm Recent Developments/Updates

3 Competitive Environment: GLP-1 Receptor Agonist Drugs by Manufacturer

  • 3.1 Global GLP-1 Receptor Agonist Drugs Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global GLP-1 Receptor Agonist Drugs Revenue by Manufacturer (2021-2026)
  • 3.3 Global GLP-1 Receptor Agonist Drugs Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of GLP-1 Receptor Agonist Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 GLP-1 Receptor Agonist Drugs Manufacturer Market Share in 2025
    • 3.4.3 Top 6 GLP-1 Receptor Agonist Drugs Manufacturer Market Share in 2025
  • 3.5 GLP-1 Receptor Agonist Drugs Market: Overall Company Footprint Analysis
    • 3.5.1 GLP-1 Receptor Agonist Drugs Market: Region Footprint
    • 3.5.2 GLP-1 Receptor Agonist Drugs Market: Company Product Type Footprint
    • 3.5.3 GLP-1 Receptor Agonist Drugs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global GLP-1 Receptor Agonist Drugs Market Size by Region
    • 4.1.1 Global GLP-1 Receptor Agonist Drugs Sales Quantity by Region (2021-2032)
    • 4.1.2 Global GLP-1 Receptor Agonist Drugs Consumption Value by Region (2021-2032)
    • 4.1.3 Global GLP-1 Receptor Agonist Drugs Average Price by Region (2021-2032)
  • 4.2 North America GLP-1 Receptor Agonist Drugs Consumption Value (2021-2032)
  • 4.3 Europe GLP-1 Receptor Agonist Drugs Consumption Value (2021-2032)
  • 4.4 Asia-Pacific GLP-1 Receptor Agonist Drugs Consumption Value (2021-2032)
  • 4.5 South America GLP-1 Receptor Agonist Drugs Consumption Value (2021-2032)
  • 4.6 Middle East & Africa GLP-1 Receptor Agonist Drugs Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global GLP-1 Receptor Agonist Drugs Sales Quantity by Type (2021-2032)
  • 5.2 Global GLP-1 Receptor Agonist Drugs Consumption Value by Type (2021-2032)
  • 5.3 Global GLP-1 Receptor Agonist Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global GLP-1 Receptor Agonist Drugs Sales Quantity by Application (2021-2032)
  • 6.2 Global GLP-1 Receptor Agonist Drugs Consumption Value by Application (2021-2032)
  • 6.3 Global GLP-1 Receptor Agonist Drugs Average Price by Application (2021-2032)

7 North America

  • 7.1 North America GLP-1 Receptor Agonist Drugs Sales Quantity by Type (2021-2032)
  • 7.2 North America GLP-1 Receptor Agonist Drugs Sales Quantity by Application (2021-2032)
  • 7.3 North America GLP-1 Receptor Agonist Drugs Market Size by Country
    • 7.3.1 North America GLP-1 Receptor Agonist Drugs Sales Quantity by Country (2021-2032)
    • 7.3.2 North America GLP-1 Receptor Agonist Drugs Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe GLP-1 Receptor Agonist Drugs Sales Quantity by Type (2021-2032)
  • 8.2 Europe GLP-1 Receptor Agonist Drugs Sales Quantity by Application (2021-2032)
  • 8.3 Europe GLP-1 Receptor Agonist Drugs Market Size by Country
    • 8.3.1 Europe GLP-1 Receptor Agonist Drugs Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe GLP-1 Receptor Agonist Drugs Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific GLP-1 Receptor Agonist Drugs Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific GLP-1 Receptor Agonist Drugs Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific GLP-1 Receptor Agonist Drugs Market Size by Region
    • 9.3.1 Asia-Pacific GLP-1 Receptor Agonist Drugs Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific GLP-1 Receptor Agonist Drugs Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America GLP-1 Receptor Agonist Drugs Sales Quantity by Type (2021-2032)
  • 10.2 South America GLP-1 Receptor Agonist Drugs Sales Quantity by Application (2021-2032)
  • 10.3 South America GLP-1 Receptor Agonist Drugs Market Size by Country
    • 10.3.1 South America GLP-1 Receptor Agonist Drugs Sales Quantity by Country (2021-2032)
    • 10.3.2 South America GLP-1 Receptor Agonist Drugs Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa GLP-1 Receptor Agonist Drugs Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa GLP-1 Receptor Agonist Drugs Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa GLP-1 Receptor Agonist Drugs Market Size by Country
    • 11.3.1 Middle East & Africa GLP-1 Receptor Agonist Drugs Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa GLP-1 Receptor Agonist Drugs Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 GLP-1 Receptor Agonist Drugs Market Drivers
  • 12.2 GLP-1 Receptor Agonist Drugs Market Restraints
  • 12.3 GLP-1 Receptor Agonist Drugs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of GLP-1 Receptor Agonist Drugs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of GLP-1 Receptor Agonist Drugs
  • 13.3 GLP-1 Receptor Agonist Drugs Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 GLP-1 Receptor Agonist Drugs Typical Distributors
  • 14.3 GLP-1 Receptor Agonist Drugs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global GLP-1 Receptor Agonist Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    GLP-1 receptor agonists are a class of medications used primarily in the treatment of type 2 diabetes mellitus.They mimic the action of glucagon-like peptide-1(GLP-1),a hormone that stimulates insulin secretion from the pancreas in response to food intake,thereby lowering blood sugar levels.These drugs also suppress glucagon secretion,slow gastric emptying,and promote satiety, leading to potential weight loss.
    This report is a detailed and comprehensive analysis for global GLP-1 Receptor Agonist Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global GLP-1 Receptor Agonist Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global GLP-1 Receptor Agonist Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global GLP-1 Receptor Agonist Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global GLP-1 Receptor Agonist Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for GLP-1 Receptor Agonist Drugs
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global GLP-1 Receptor Agonist Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Renhui Biopharmaceutical, Huadong Medicine, Sino Biopharm, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    GLP-1 Receptor Agonist Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Short-acting Preparations
    Long-acting Preparations
    Ultra-long-acting Preparations
    Market segment by Application
    Type 2 Diabetes
    Obesity
    Major players covered
    Novo Nordisk
    Eli Lilly
    AstraZeneca
    Sanofi
    GSK
    Hanson
    Shanghai Renhui Biopharmaceutical
    Huadong Medicine
    Sino Biopharm
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe GLP-1 Receptor Agonist Drugs product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of GLP-1 Receptor Agonist Drugs, with price, sales quantity, revenue, and global market share of GLP-1 Receptor Agonist Drugs from 2021 to 2026.
    Chapter 3, the GLP-1 Receptor Agonist Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the GLP-1 Receptor Agonist Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and GLP-1 Receptor Agonist Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1 Receptor Agonist Drugs.
    Chapter 14 and 15, to describe GLP-1 Receptor Agonist Drugs sales channel, distributors, customers, research findings and conclusion.

    Buy now